

Immune Check Point Inhibitor-United States Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/I034BBD6C1BEN.html

Date: December 2017

Pages: 139

Price: US\$ 3,480.00 (Single User License)

ID: I034BBD6C1BEN

Abstracts

Report Summary

Immune Check Point Inhibitor-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Immune Check Point Inhibitor industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Immune Check Point Inhibitor 2013-2017, and development forecast 2018-2023

Main market players of Immune Check Point Inhibitor in United States, with company and product introduction, position in the Immune Check Point Inhibitor market Market status and development trend of Immune Check Point Inhibitor by types and applications

Cost and profit status of Immune Check Point Inhibitor, and marketing status Market growth drivers and challenges

The report segments the United States Immune Check Point Inhibitor market as:

United States Immune Check Point Inhibitor Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England
The Middle Atlantic



The Midwest

The West

The South

Southwest

United States Immune Check Point Inhibitor Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

CTLA 4

PD₁

Others

United States Immune Check Point Inhibitor Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Medical Care

Experiment

Others

United States Immune Check Point Inhibitor Market: Players Segment Analysis (Company and Product introduction, Immune Check Point Inhibitor Sales Volume, Revenue, Price and Gross Margin):

Advaxis

Agenus

Amgen

Bristol Myers Squibb

Faron Pharmaceuticals

Genentech

Genocea

Incyte Corporation

Innate Pharma

Kite Pharma

MacroGenics

Merck

NewLink Genetics Corp

Sorrento Therapeutics

TG Therapeutics



In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF IMMUNE CHECK POINT INHIBITOR

- 1.1 Definition of Immune Check Point Inhibitor in This Report
- 1.2 Commercial Types of Immune Check Point Inhibitor
 - 1.2.1 CTLA
 - 1.2.2 PD
 - 1.2.3 Others
- 1.3 Downstream Application of Immune Check Point Inhibitor
 - 1.3.1 Medical Care
 - 1.3.2 Experiment
 - 1.3.3 Others
- 1.4 Development History of Immune Check Point Inhibitor
- 1.5 Market Status and Trend of Immune Check Point Inhibitor 2013-2023
- 1.5.1 United States Immune Check Point Inhibitor Market Status and Trend 2013-2023
- 1.5.2 Regional Immune Check Point Inhibitor Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Immune Check Point Inhibitor in United States 2013-2017
- 2.2 Consumption Market of Immune Check Point Inhibitor in United States by Regions
- 2.2.1 Consumption Volume of Immune Check Point Inhibitor in United States by Regions
- 2.2.2 Revenue of Immune Check Point Inhibitor in United States by Regions
- 2.3 Market Analysis of Immune Check Point Inhibitor in United States by Regions
 - 2.3.1 Market Analysis of Immune Check Point Inhibitor in New England 2013-2017
- 2.3.2 Market Analysis of Immune Check Point Inhibitor in The Middle Atlantic 2013-2017
 - 2.3.3 Market Analysis of Immune Check Point Inhibitor in The Midwest 2013-2017
 - 2.3.4 Market Analysis of Immune Check Point Inhibitor in The West 2013-2017
 - 2.3.5 Market Analysis of Immune Check Point Inhibitor in The South 2013-2017
 - 2.3.6 Market Analysis of Immune Check Point Inhibitor in Southwest 2013-2017
- 2.4 Market Development Forecast of Immune Check Point Inhibitor in United States 2018-2023
- 2.4.1 Market Development Forecast of Immune Check Point Inhibitor in United States 2018-2023
- 2.4.2 Market Development Forecast of Immune Check Point Inhibitor by Regions 2018-2023



CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole United States Market Status by Types
- 3.1.1 Consumption Volume of Immune Check Point Inhibitor in United States by Types
- 3.1.2 Revenue of Immune Check Point Inhibitor in United States by Types
- 3.2 United States Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in New England
 - 3.2.2 Market Status by Types in The Middle Atlantic
 - 3.2.3 Market Status by Types in The Midwest
 - 3.2.4 Market Status by Types in The West
 - 3.2.5 Market Status by Types in The South
- 3.2.6 Market Status by Types in Southwest
- 3.3 Market Forecast of Immune Check Point Inhibitor in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Immune Check Point Inhibitor in United States by Downstream Industry
- 4.2 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in New England
- 4.2.2 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in The Middle Atlantic
- 4.2.3 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in The Midwest
- 4.2.4 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in The West
- 4.2.5 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in The South
- 4.2.6 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in Southwest
- 4.3 Market Forecast of Immune Check Point Inhibitor in United States by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IMMUNE CHECK POINT INHIBITOR



- 5.1 United States Economy Situation and Trend Overview
- 5.2 Immune Check Point Inhibitor Downstream Industry Situation and Trend Overview

CHAPTER 6 IMMUNE CHECK POINT INHIBITOR MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

- 6.1 Sales Volume of Immune Check Point Inhibitor in United States by Major Players
- 6.2 Revenue of Immune Check Point Inhibitor in United States by Major Players
- 6.3 Basic Information of Immune Check Point Inhibitor by Major Players
- 6.3.1 Headquarters Location and Established Time of Immune Check Point Inhibitor Major Players
 - 6.3.2 Employees and Revenue Level of Immune Check Point Inhibitor Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 IMMUNE CHECK POINT INHIBITOR MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Advaxis
 - 7.1.1 Company profile
 - 7.1.2 Representative Immune Check Point Inhibitor Product
- 7.1.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Advaxis
- 7.2 Agenus
 - 7.2.1 Company profile
 - 7.2.2 Representative Immune Check Point Inhibitor Product
- 7.2.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Agenus
- 7.3 Amgen
 - 7.3.1 Company profile
 - 7.3.2 Representative Immune Check Point Inhibitor Product
- 7.3.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Amgen
- 7.4 Bristol Myers Squibb
 - 7.4.1 Company profile
 - 7.4.2 Representative Immune Check Point Inhibitor Product



- 7.4.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Bristol Myers Squibb
- 7.5 Faron Pharmaceuticals
 - 7.5.1 Company profile
 - 7.5.2 Representative Immune Check Point Inhibitor Product
- 7.5.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Faron Pharmaceuticals
- 7.6 Genentech
 - 7.6.1 Company profile
 - 7.6.2 Representative Immune Check Point Inhibitor Product
- 7.6.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Genentech
- 7.7 Genocea
 - 7.7.1 Company profile
 - 7.7.2 Representative Immune Check Point Inhibitor Product
- 7.7.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Genocea
- 7.8 Incyte Corporation
 - 7.8.1 Company profile
 - 7.8.2 Representative Immune Check Point Inhibitor Product
- 7.8.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Incyte Corporation
- 7.9 Innate Pharma
 - 7.9.1 Company profile
 - 7.9.2 Representative Immune Check Point Inhibitor Product
- 7.9.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Innate Pharma
- 7.10 Kite Pharma
 - 7.10.1 Company profile
 - 7.10.2 Representative Immune Check Point Inhibitor Product
- 7.10.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Kite Pharma
- 7.11 MacroGenics
 - 7.11.1 Company profile
 - 7.11.2 Representative Immune Check Point Inhibitor Product
 - 7.11.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of
- MacroGenics
- 7.12 Merck
 - 7.12.1 Company profile



- 7.12.2 Representative Immune Check Point Inhibitor Product
- 7.12.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Merck
- 7.13 NewLink Genetics Corp
 - 7.13.1 Company profile
- 7.13.2 Representative Immune Check Point Inhibitor Product
- 7.13.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of NewLink Genetics Corp
- 7.14 Sorrento Therapeutics
 - 7.14.1 Company profile
 - 7.14.2 Representative Immune Check Point Inhibitor Product
- 7.14.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Sorrento Therapeutics
- 7.15 TG Therapeutics
 - 7.15.1 Company profile
 - 7.15.2 Representative Immune Check Point Inhibitor Product
- 7.15.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of TG Therapeutics

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IMMUNE CHECK POINT INHIBITOR

- 8.1 Industry Chain of Immune Check Point Inhibitor
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IMMUNE CHECK POINT INHIBITOR

- 9.1 Cost Structure Analysis of Immune Check Point Inhibitor
- 9.2 Raw Materials Cost Analysis of Immune Check Point Inhibitor
- 9.3 Labor Cost Analysis of Immune Check Point Inhibitor
- 9.4 Manufacturing Expenses Analysis of Immune Check Point Inhibitor

CHAPTER 10 MARKETING STATUS ANALYSIS OF IMMUNE CHECK POINT INHIBITOR

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing



- 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Immune Check Point Inhibitor-United States Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/I034BBD6C1BEN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/l034BBD6C1BEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970